Acumen and deCODE Chemistry Initiate Drug Discovery Research
News Dec 23, 2005
The program will initially involve a hit-to-lead campaign focused on exploring the high-quality screening hits that Acumen identified in its small molecule anti-ADDLplatform.
As validated lead series develop, deCODE chemistry will conduct lead optimization focused on potency in Acumen’s assay and optimization of pharmaceutical properties.
Under the terms of the agreement, deCODE chemistry will provide medicinal chemistry services to Acumen on a fee- for-service basis, to include services from the Medicinal Chemistry and Drug Safety and Metabolism groups of deCODE chemistry.
"We are delighted to have the opportunity to work with Acumen Pharmaceuticals on this exciting research program," said Dr. David Zembower, Vice President of Chemistry at deCODE chemistry.
"Our service platform is ideally suited to help advance Acumen’s research program and allow them to achieve their corporate goals."
"After an in-depth evaluation of many service providers, we were very pleased to select deCODE chemistry as Acumen’s medicinal chemistry services provider," said Dr. William Goure, Vice President of Business Development and Director of Chemistry at Acumen.
"We have been working with deCODE chemistry for several months, and they have met all our expectations of providing high quality medicinal chemistry to advance Acumen’s drug discovery and development program."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE